ArticleCancer causes & control : CCC2025
Changing pace of human papillomavirus vaccination among U.S. adolescents and young adults: the National Health and Nutrition Examination Survey, 2007-August 2023.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate whether HPV vaccination prevalence among eligible U.S. individuals has increased steadily since vaccine introduction and to characterize trends across demographic subgroups.
methodsUsing National Health and Nutrition Examination Survey data (2007-August 2023) among individuals aged 9-26 years, we assessed trends in HPV vaccination prevalence (≥ 1 dose) with joinpoint regression to identify inflection points and estimate annual percent changes (APCs). Analyses were stratified by sex, age, and race/ethnicity.
resultsVaccination prevalence increased from 14.1% (95% CI, 10.1-19.3) in 2007-2008 to 49.1% (95% CI, 44.5-53.7) in 2021-2023 (APC, 6.8%; p = 0.001). Females experienced an early sharp rise (APC, 24.0%; p < 0.001) through 2011-2012, followed by slower growth thereafter (APC, 3.7%; p = 0.004). Male vaccination increased steadily (APC, 11.3%; p < 0.001). By 2021-2023, prevalence was highest among 13-17-year-olds (58.2%) and lowest among 9-12-year-olds (26.2%). Black individuals had the lowest vaccination prevalence of any racial/ethnic group (29.3%) and experienced a reversal of prior gains after 2015-2016 (APC, - 2.3%; p = 0.34).
conclusionsHPV vaccination prevalence more than tripled between 2007 and 2023, but the pace of growth slowed among females and reversed among Black individuals, which may exacerbate existing disparities in HPV-related cancer burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.